Legato Capital Management LLC Has $537,000 Holdings in Glaukos Co. (NYSE:GKOS)

Legato Capital Management LLC cut its holdings in shares of Glaukos Co. (NYSE:GKOS) by 52.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,540 shares of the medical instruments supplier’s stock after selling 5,072 shares during the period. Legato Capital Management LLC’s holdings in Glaukos were worth $537,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after purchasing an additional 72,159 shares during the period. Brown Capital Management LLC increased its stake in shares of Glaukos by 3.4% in the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock valued at $214,448,000 after acquiring an additional 89,420 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Glaukos by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after acquiring an additional 31,213 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Glaukos by 23.7% in the 4th quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock valued at $62,800,000 after acquiring an additional 151,415 shares during the last quarter. Finally, Iron Triangle Partners LP increased its stake in shares of Glaukos by 75.6% in the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after acquiring an additional 184,919 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Needham & Company LLC upped their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Citigroup cut Glaukos from a “buy” rating to a “neutral” rating and upped their price target for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a research note on Friday, August 2nd. Finally, Truist Financial reissued a “buy” rating and set a $145.00 target price (up from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $127.73.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $13,216,581.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Glaukos news, Director Marc Stapley sold 6,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the sale, the director now directly owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total transaction of $646,800.00. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $13,216,581.84. The disclosure for this sale can be found here. Insiders sold a total of 46,000 shares of company stock valued at $5,550,740 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Glaukos Stock Up 1.4 %

Shares of GKOS opened at $135.26 on Wednesday. The company has a current ratio of 5.48, a quick ratio of 4.68 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $135.63. The firm’s 50 day moving average is $120.96 and its 200-day moving average is $106.96. The stock has a market capitalization of $6.81 billion, a PE ratio of -46.97 and a beta of 1.05.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.55) EPS. Equities research analysts forecast that Glaukos Co. will post -2.25 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.